Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13621571 | 1.00 | TAAR1 (0.57) | TAAR1SIGMAR1SLC18A2HTTALDH1A1 | |
| SCHEMBL13621464 | 1.00 | TAAR1 (0.57) | TAAR1SIGMAR1SLC18A2HTTALDH1A1 | |
| SCHEMBL11099393 | 0.88 | SMN1; SMN2 (0.49) | TAAR1SIGMAR1SLC18A2HTTALDH1A1 | |
| SCHEMBL9321453 | 0.87 | SLC6A2 (0.59) | TAAR1SIGMAR1SLC18A2HTTALDH1A1 | |
| SCHEMBL27629283 | 0.87 | TAAR1 (0.44) | TAAR1SIGMAR1SLC18A2HTTALDH1A1 | |
| SCHEMBL9322810 | 0.87 | SLC6A4 (0.55) | TAAR1SIGMAR1SLC18A2HTTALDH1A1 | |
| Maleic Acid SCHEMBL7272390 | 0.86 | TAAR1 (0.55) | TAAR1HTTALDH1A1NCOA1SMN1; SMN2 | |
| Fumaric Acid SCHEMBL7272401 | 0.86 | TAAR1 (0.55) | TAAR1HTTALDH1A1NCOA1SMN1; SMN2 | |
| SCHEMBL19257741 | 0.84 | SLC6A3 (0.50) | TAAR1SIGMAR1SLC18A2HTTALDH1A1 | |
| SCHEMBL9054645 | 0.82 | OPRK1 (0.50) | TAAR1SIGMAR1SLC18A2KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2020141734-A1 | METHOD FOR PREPARING CHIRAL GAMMA-LACTAM COMPOUND AND METAL COMPLEX THEREFOR | 기초과학연구원 | 2020-07-09 | — | — | WO | disclosed |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3485882-A1 | COMPOSITIONS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | Case Western Reserve University (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2948135-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-01-11 | — | — | US | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-0279937-B1 | 2-AMINOACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1991-10-09 | — | — | EP | disclosed |
| US-5047541-A | 2-azacyclocarboxamide derivatives | FISONS CORPORATION (US) | 1991-09-10 | — | — | US | disclosed |
| WO-1991011995-A1 | ARYLALKYL-AMINES AND -AMIDES HAVING ANTICONVULSANT AND NEUROPROTECTIVE PROPERTIES | FISONS CORPORATION (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0401253-A1 | 2-AMINO ACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1990-12-12 | — | — | EP | disclosed |
| EP-0356035-A2 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | Astra Aktiebolag (SE) | 1990-02-28 | — | — | EP | disclosed |
| US-4871872-A | 2-[(2-aminoacetyl)amino]acetamide derivatives | FISONS CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0326240-A1 | 2-Amino acetamide derivatives | FISONS CORPORATION (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006646-A1 | 2-AMINO ACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0279937-A1 | 2-Aminoacetamide derivatives | FISONS CORPORATION (US) | 1988-08-31 | — | — | EP | disclosed |
| EP-0278089-A2 | 2-Azacyclocarboxamide derivatives | FISONS CORPORATION (a Massachusetts corporation) (US) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | TAAR1 3434/4885SIGMAR1 517/4885SLC18A2 4204/4885 |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | TAAR1 123/4885SIGMAR1 232/4885SLC18A2 62/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | TAAR1 3354/4885SIGMAR1 3483/4885SLC18A2 1168/4885 |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | GRIN2A, GRIN2C, GRIN2D | TAAR1 193/4885SIGMAR1 1401/4885SLC18A2 58/4885 |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2A, GRIN2C, GRIN2D | TAAR1 193/4885SIGMAR1 1401/4885SLC18A2 58/4885 |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | MECP2, GRIN2A, GRIN2B | TAAR1 669/4885SIGMAR1 1494/4885SLC18A2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.